Publication | Open Access

Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study

Gastrointestinal OncologyMedicineCancer ManagementRegorafenib Dose-optimisationColorectal CancerPharmacotherapyOncologyRadiation OncologyRadiologyHealth Sciences